Undisclosed CAR-T / KiraGen Bio - LARVOL DELTA

KiraGen Bio and Flash BioSolutions Announce Innovative Partnership to Revolutionize CAR-T Therapies for Solid Tumors (Flash Therapeutics Press Release) - "KiraGen Bio...is pleased to announce today a strategic partnership with Flash BioSolutions, a leading CDMO providing state-of-the-art lentiviral particles. This collaboration aims to fully harness the potential of CAR-T (Chimeric Antigen Receptor T-cell) therapies in cancer treatment...Through this alliance, KiraGen Bio will leverage the advanced expertise of Flash BioSolutions and its flagship technology, LentiCare. This cutting-edge lentiviral platform will be seamlessly integrated into the development of KiraGen Bio's groundbreaking CAR-T therapies, playing a crucial role in the Proof of Concept stage and beyond....By integrating these AI-powered gene editing capabilities with the high-quality lentiviral vectors provided by Flash BioSolutions, KiraGen Bio is poised to unlock the full potential of CAR-T therapies for solid tumors, addressing a critical unmet need in cancer treatment."

Licensing / partnership • Oncology • Solid Tumor